Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

5. November 2018 aktualisiert von: MedImmune LLC

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma

The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

584

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Bulgarien
      • Plovdiv, Bulgarien, 4002
        • Research Site
      • Sofia, Bulgarien, 1431
        • Research Site
      • Sofia, Bulgarien, 1202
        • Research Site
      • Sofia, Bulgarien, 1233
        • Research Site
      • Sofia, Bulgarien, 1750
        • Research Site
      • Sofia, Bulgarien, 1606
        • Research Site
      • Velingrad, Bulgarien, 4600
        • Research Site
  • Israel
      • Ashkelon, Israel, 78278
        • Research Site
      • Haifa, Israel, 34362
        • Research Site
      • Jerusalem, Israel, 91120
        • Research Site
      • Kfar-Saba, Israel, 44281
        • Research Site
      • Petach Tikva, Israel
        • Research Site
      • Rehovot, Israel, 7661041
        • Research Site
      • Tel Hashomer, Israel, 52621
        • Research Site
  • Japan
      • Chuo-ku, Japan, 103-0028
        • Research Site
      • Chuo-ku, Japan, 103-0027
        • Research Site
      • Chuo-ku, Japan, 104-8560
        • Research Site
      • Fujisawa-shi, Japan, 251-8550
        • Research Site
      • Kiyose-shi, Japan, 204-8585
        • Research Site
      • Kurume-shi, Japan, 830-0011
        • Research Site
      • Maebashi-shi, Japan, 371-0054
        • Research Site
      • Ora-gun, Japan, 370-0615
        • Research Site
      • Sagamihara-shi, Japan, 228-0815
        • Research Site
      • Saitama-Ken, Japan, 338-8553
        • Research Site
      • Sapporo-shi, Japan, 060-0033
        • Research Site
      • Taito-ku, Japan, 111-0051
        • Research Site
      • Toshima-ku, Japan, 171-0014
        • Research Site
      • Yokkaichi-shi, Japan, 510-8567
        • Research Site
  • Lettland
      • Daugavpils, Lettland, LV-5401
        • Research Site
      • Rezekne, Lettland, LV-4600
        • Research Site
      • Riga, Lettland, 1001
        • Research Site
      • Riga, Lettland, LV1002
        • Research Site
      • Riga, Lettland, LV-1038
        • Research Site
      • Riga, Lettland, LV1010
        • Research Site
  • Litauen
      • Kaunas, Litauen, LT50009
        • Research Site
      • Klaipeda, Litauen, 92288
        • Research Site
      • Klaipeda, Litauen, 92231
        • Research Site
  • Serbien
      • Belgrade, Serbien, 11000
        • Research Site
      • Kragujevac, Serbien, 34000
        • Research Site
      • Sremska Kamenica, Serbien, 21204
        • Research Site
  • Slowakei
      • Bardejov, Slowakei, 085 01
        • Research Site
      • Bratislava, Slowakei, 84108
        • Research Site
      • Ilava, Slowakei, 01901
        • Research Site
      • Kosice, Slowakei, 040 01
        • Research Site
      • Levice, Slowakei, 934 01
        • Research Site
      • Nove Zamky, Slowakei, 940 01
        • Research Site
      • Poprad, Slowakei, 058 01
        • Research Site
      • Spisska Nova Ves, Slowakei, 052 01
        • Research Site
      • Sturovo, Slowakei, 94301
        • Research Site
      • Surany, Slowakei, 94201
        • Research Site
      • Topolcany, Slowakei, 95501
        • Research Site
      • Zvolen, Slowakei, 96001
        • Research Site
  • Südafrika
      • Durban, Südafrika, 4068
        • Research Site
      • Middelburg, Südafrika, 1055
        • Research Site
      • Pretoria, Südafrika, 0181
        • Research Site
      • Pretoria, Südafrika, 0183
        • Research Site
  • Tschechien
      • Brandys nad Labem, Tschechien, 250 01
        • Research Site
      • Hradec Kralove, Tschechien, 500 05
        • Research Site
      • Mlada Boleslav, Tschechien, 293 01
        • Research Site
      • Praha 4, Tschechien, 14059
        • Research Site
      • Praha 8, Tschechien, 180 81
        • Research Site
      • Praha 8, Tschechien, 180 00
        • Research Site
      • Strakonice, Tschechien, 38601
        • Research Site
  • Ukraine
      • Dnipropetrovsk, Ukraine, 49051
        • Research Site
      • Ivano-Frankivsk, Ukraine, 76012
        • Research Site
      • Kyiv, Ukraine, 04050
        • Research Site
      • Kyiv, Ukraine, 02091
        • Research Site
      • Kyiv, Ukraine, 03680
        • Research Site
      • Mykolayiv, Ukraine, 54003
        • Research Site
      • Odessa, Ukraine, 65039
        • Research Site
      • Poltava, Ukraine, 36038
        • Research Site
      • Suprunivka Vil., Poltava Regio, Ukraine, 36028
        • Research Site
      • Vinnytsia, Ukraine, 21029
        • Research Site
      • Zaporizhzhya, Ukraine, 69600
        • Research Site
      • Zaporizhzhya, Ukraine, 69035
        • Research Site
  • Ungarn
      • Balassagyarmat, Ungarn, 2660
        • Research Site
      • Budapest, Ungarn, 1125
        • Research Site
      • Budapest, Ungarn, 1529
        • Research Site
      • Budapest, Ungarn, 1033
        • Research Site
      • Csorna, Ungarn, 9300
        • Research Site
      • Debrecen, Ungarn, 4032
        • Research Site
      • Farkasgyepü, Ungarn, 8582
        • Research Site
      • Gödöllő, Ungarn, 2100
        • Research Site
      • Komarom, Ungarn, 2900
        • Research Site
      • Mateszalka, Ungarn, 4700
        • Research Site
      • Nagykanizsa, Ungarn, 8800
        • Research Site
      • Szeged, Ungarn, H-6722
        • Research Site
      • Százhalombatta, Ungarn, 2440
        • Research Site
      • Torokbalint, Ungarn, 2045
        • Research Site
  • Vereinigte Staaten
    • California
      • Los Angeles, California, Vereinigte Staaten, 90025
        • Research Site
      • Los Angeles, California, Vereinigte Staaten, 90048
        • Research Site
    • Florida
      • Miami, Florida, Vereinigte Staaten, 33133
        • Research Site
      • Oviedo, Florida, Vereinigte Staaten, 32765
        • Research Site
    • Georgia
      • Savannah, Georgia, Vereinigte Staaten, 31406
        • Research Site
    • Illinois
      • Peoria, Illinois, Vereinigte Staaten, 61602
        • Research Site
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21224
        • Research Site
    • Minnesota
      • Rochester, Minnesota, Vereinigte Staaten, 55905
        • Research Site
    • New York
      • New York, New York, Vereinigte Staaten, 10016
        • Research Site
      • New York, New York, Vereinigte Staaten, 10029
        • Research Site
    • North Carolina
      • Charlotte, North Carolina, Vereinigte Staaten, 28277
        • Research Site
      • Charlotte, North Carolina, Vereinigte Staaten, 28207
        • Research Site
    • Ohio
      • Dublin, Ohio, Vereinigte Staaten, 43016
        • Research Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73120
        • Research Site
    • South Carolina
      • Rock Hill, South Carolina, Vereinigte Staaten, 29732
        • Research Site
      • Spartanburg, South Carolina, Vereinigte Staaten, 29303
        • Research Site
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77070
        • Research Site
    • Virginia
      • Richmond, Virginia, Vereinigte Staaten, 23220
        • Research Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age 18 through 75
  • Body mass index (BMI) between 18-40 kg/m2 and weight greater than or equal 40 kg
  • Documented physician-diagnosed asthma - Subjects must have received a physician-prescribed asthma controller regimen with medium- or high-dose inhaled corticosteroids (ICS) plus long acting β2 agonist (LABA) -If on asthma controller medications in addition to ICS plus LABA, the dose of the other asthma controller medications (leukotriene receptor inhibitors, theophylline, secondary ICS, long-acting anti-muscarinics (LAMA), cromones, or maintenance oral prednisone or equivalent up to a maximum of 10 mg daily or 20 mg every other day for the maintenance treatment of asthma) must be stable. -Subjects must have a documented history of at least 2 asthma exacerbation events OR at least 1 severe asthma exacerbation resulting in hospitalization within the 12 months prior to first study visit.

Exclusion Criteria:

  • Diagnosis of vocal cord dysfunction, reactive airways dysfunction syndrome, hyperventilation and panic attacks, or other mimics of asthma.
  • Current smokers or subjects with a smoking history of ≥ 10 pack years
  • Former smokers with < 10 pack years must have stopped for at least 1 year to be eligible.
  • Any concomitant respiratory disease that in the opinion of the investigator and/or medical monitor will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (eg, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, bronchiectasis, allergic bronchopulmonary aspergillosis, Churg-Strauss syndrome).
  • Evidence of active liver disease.
  • History of Cancer, except for basal cell carcinoma or insitu carcinoma of the cervix treated with apparent success with curative therapy or other malignancies are eligible provided that curative therapy was completed -Known history of active tuberculosis (TB)
  • History of anaphylaxis to any biologic therapy
  • Positive medical history for hepatitis B or C
  • Subject with human immunodeficiency virus (HIV) or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Placebo
Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Arzneimittel: Placebo
Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Experimental: MEDI9929 70 mg
Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Arzneimittel: MEDI9929 70 mg
Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Experimental: MEDI9929 210 mg
Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Arzneimittel: MEDI9929 210 mg
Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Experimental: MEDI9929 280 mg
Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Arzneimittel: MEDI9929 280 mg
Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Annualized Asthma Exacerbation Rate (AER) Through Week 52
Zeitfenster: Week 0 (Day 1) up to Week 52
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
Week 0 (Day 1) up to Week 52

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Reduction in AER on Subpopulations at Week 52
Zeitfenster: Week 52
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Reduction in AER was evaluated in pre-specified subpopulations (blood eosinophil count [eosinophilic and non-eosinophilic], T helper cell 2 [Th2] status [high and low], Fraction of exhaled nitric oxide [FENO] [high and low], serum periostin [high and low], current post bronchodilator forced expiratory volume in 1 second [Post-BD FEV1] reversibility- yes, allergic and non-allergic) of asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up. Also, the high or low was determined using median value.
Week 52
Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Week 52
Zeitfenster: Baseline (Week 0 [Day 1]) to Week 52
Forced expiratory volume in 1 second and forced vital capacity measures taken before bronchodilator use were reported.
Baseline (Week 0 [Day 1]) to Week 52
Change From Baseline in FEV1 on Subpopulations at Week 52
Zeitfenster: Baseline and up to Week 52
Forced expiratory volume in one second (FEV1) was evaluated in pre-specified subpopulations of asthma. The data presented in the below table for this outcome measure is for pre-bronchodilator FEV1.
Baseline and up to Week 52
Change From Baseline in Post-bronchodilator (Post-BD) FEV1 and FVC at Week 52
Zeitfenster: Baseline (Week 0 [Day 1]) to Week 52
Forced expiratory volume in 1 second and forced vital capacity measures taken after bronchodilator use were reported.
Baseline (Week 0 [Day 1]) to Week 52
Change From Baseline in Overall Symptoms Score on Subpopulations at Week 52
Zeitfenster: Baseline and up to Week 52
Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Overall symptom score is the average of scores of daytime severity, daytime frequency, and nighttime severity symptoms. The daytime frequency and severity items are scored from 0 to 4, where a higher score indicates greater frequency/severity and nighttime severity item is scored from 0 to 4 , where a higher score indicates greater severity. Overall symptom score ranges from 0 to 4, where lower score indicates better asthma symptom while, higher score indicates worse asthma symptom.
Baseline and up to Week 52
Change From Baseline in Asthma Symptoms Measured by Asthma Daily Diary at Week 52
Zeitfenster: Baseline (Week 0 [Day 1]) and Week 52
Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Symptom score values for night time assessment is 0 (no asthma symptom) to 3 (unable to sleep because of asthma) and symptom score values for day time assessment is 0 (no asthma symptom) to 3 (unable to do normal activities due to asthma). Total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom.
Baseline (Week 0 [Day 1]) and Week 52
Change From Baseline in Asthma Symptoms Measured by Asthma Control Questionnaire (ACQ-6) Score at Week 52
Zeitfenster: Baseline (Week 0 [Day 1]) and Week 52
The ACQ is a patient-reported questionnaire assessing asthma symptoms (ie, night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing) and daily rescue bronchodilator use and FEV1. The ACQ-6 is a shortened version of the ACQ that omits the FEV1 measurement from the original ACQ score. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled).
Baseline (Week 0 [Day 1]) and Week 52
Rate of Severe Asthma Exacerbation Through Week 52
Zeitfenster: Week 0 (Day 1) up to Week 52
A severe asthma exacerbation is defined as an event that resulted in hospitalization. The severe AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
Week 0 (Day 1) up to Week 52
Time to First Asthma Exacerbation Through Week 52
Zeitfenster: Week 0 (Day 1) through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first asthma exacerbation was reported.
Week 0 (Day 1) through Week 52
Time to First Severe Asthma Exacerbation Through Week 52
Zeitfenster: Week 0 (Day 1) through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first severe asthma exacerbations (hospitalization) were reported.
Week 0 (Day 1) through Week 52
Number of Participants With at Least One Asthma Exacerbations Through Week 52
Zeitfenster: Week 0 (Day 1) through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.
Week 0 (Day 1) through Week 52
Number of Participants With at Least One Severe Asthma Exacerbations Through Week 52
Zeitfenster: Week 0 (Day 1) through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Participants with severe asthma exacerbations (hospitalization) were reported.
Week 0 (Day 1) through Week 52
Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ [S]) Overall Score at Week 52
Zeitfenster: Baseline (Week 0 [Day 1]) and Week 52
The AQLQ(S) +12 is a 32-item questionnaire that measures the health-related quality of life experienced by asthma participants. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli) scaled on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment).
Baseline (Week 0 [Day 1]) and Week 52
Change From Baseline in European Quality of Life-5 Dimensions 5 Level Version (EQ-5D-5L) Health State Evaluation at Week 52
Zeitfenster: Baseline (Week 0 [Day 1]) and Week 52
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1. A higher score indicates better health state. The second component is a self-perceived health score which is assessed using a visual analogue scale (VAS) that ranged from 0 to 100, where 0 indicated the worst health you can imagine and 100 indicated the best health you can imagine.
Baseline (Week 0 [Day 1]) and Week 52
Total Amount of Study Drug Exposure
Zeitfenster: Week 0 (Day 1) through Week 52
The total amount of study drug exposure (in milligram) for the entire study period was summarized.
Week 0 (Day 1) through Week 52
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Zeitfenster: Day 1 upto Week 64
An adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of medicinal product, whether or not considered related to medicinal product. Serious adverse event is any adverse event that resulted in death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug, for the period until and including the follow-up period (Week 64).
Day 1 upto Week 64
Number of Participants With TEAEs Related to Vital Sign Parameters
Zeitfenster: Day 1 upto Week 64
Adverse events observed in participants with clinically significant vital signs abnormalities were assessed.
Day 1 upto Week 64
Number of Participants With TEAEs Related to Clinical Laboratory Evaluation
Zeitfenster: Day 1 upto Week 64
An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations of blood and urine samples were performed.
Day 1 upto Week 64
Number of Participants With TEAEs Related to Electrocardiogram Evaluations
Zeitfenster: From the start of study drug administration upto Week 64
Adverse events observed in participants with clinically significant electrocardiogram abnormalities were assessed.
From the start of study drug administration upto Week 64
Mean Serum Concentrations of MEDI9929
Zeitfenster: Week 0 (Day 1) to Week 64
The mean serum concentrations of MEDI9929 was observed at specified timepoints.
Week 0 (Day 1) to Week 64
Number of Participants With Positive Antibodies to MEDI9929
Zeitfenster: Week 0 (Day 1) to Week 64
Blood samples for immunogenicity assessment included the determination of anti-drug antibodies (ADA) for MEDI9929. The number of participants with positive serum antibodies to MEDI9929 were presented.
Week 0 (Day 1) to Week 64

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

MedImmune LLC

Mitarbeiter

Amgen

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

13. Dezember 2013

Primärer Abschluss (Tatsächlich)

12. Dezember 2016

Studienabschluss (Tatsächlich)

1. März 2017

Studienanmeldedaten

Zuerst eingereicht

4. Dezember 2013

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. Februar 2014

Zuerst gepostet (Schätzen)

4. Februar 2014

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

4. Dezember 2018

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

5. November 2018

Zuletzt verifiziert

1. November 2018

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • CD-RI-MEDI9929-1146
  • 2013-003269-33 (EudraCT-Nummer)

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Asthma

Klinische Studien zur Placebo

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Algeria

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren